Navigation Links
UCSF Fresno leading-edge study lends hope to emphysema patients
Date:10/21/2008

Patients in the Valley with emphysema might soon be breathing a little easier thanks to a new airway bypass study called the Exhale Airways Stents for Emphysema (EASE) trial. The trial principal is Dr. Karl Van Gundy aided by investigators Drs. Michael Peterson, Jose Joseph, Timothy Evans and Kathryn Bilello all pulmonologists at UCSF Fresno Medical Education Program. The study is a multi-center, international trial that is designed to evaluate the safety and effectiveness of this new and innovative procedure. There are only two other sites administering the trial in California besides UCSF Fresno UC Davis Medical Center and Cedars-Sinai Medical Center in Los Angeles.

A form of chronic obstructive pulmonary disease (COPD), emphysema is a progressive lung disease that keeps air trapped inside the lungs (not allowing it to escape) resulting in shortness of breath. Since the disease develops gradually over many years, symptoms of emphysema might not occur until irreversible damage has already happened.

"COPD is the fourth leading cause of death in the United States and a significant cause of disability in the world," said Dr. Peterson, who also is chief of medicine at UCSF Fresno Medical Education Program. "Very few new treatments have become available for this disease."

The EASE trial procedure creates new pathways in the walls of the natural airways that connect the damaged inner lung tissue and the larger natural air passages. Dr. Peterson said these new passageways may provide a pathway for the trapped air in the inner lung to escape by "bypassing" the collapsing small airways. These new pathways are created using a special needle through a bronchoscope.

After each new passage is made, a small drug-eluting stent (a wire mesh similar to what is used to keep coronary arteries open in heart disease) is implanted and provides support to keep the passageway open. Dr. Peterson said opening the airway allows the trapped air to escape the lungs, thereby hopefully relieving one of the symptoms of emphysema shortness of breath.

"A previous large trial (NETT) demonstrated that some patients with emphysema are helped by surgery to reduce the volume of air in the chest. However, this is a complicated and potentially dangerous surgical procedure. The EASE trial is designed to determine if a minimally-invasive approach to reducing lung volume could benefit patients with severe COPD," Dr. Peterson said.

Both Drs. Peterson and Van Gundy are excited to offer this research approach soon to patients in the Central Valley.

"We are currently enrolling patients in this trial and we will continue to enroll patients for next year," Dr. Van Gundy said. To find out more about the study you can go online www.easetrialus.com


'/>"/>

Contact: Meghan Oreste
moreste@comcast.net
617-823-1441
Broncus Technologies
Source:Eurekalert  

Related biology news :

1. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
2. A study by the MUHC and McGill University opens a new door to understanding cancer
3. Study begins to reveal clues to the cause and progression of sepsis
4. Clones on task serve greater good, evolutionary study shows
5. New study warns limited carbon market puts 20 percent of tropical forest at risk
6. New study examines how rearing environment can alter navigation
7. Study links cat disease to flame retardants in furniture and to pet food
8. New continent and species discovered in Atlantic study
9. Study shows link between alcohol consumption and hiv disease progression
10. Feeling hot, hot, hot: New study suggests ways to control fever-induced seizures
11. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UCSF Fresno leading-edge study lends hope to emphysema patients
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute announced ... Larry Schlesinger as the Institute,s new President and ... effective May 31, 2017. He is currently the Chair of ... the Center for Microbial Interface Biology at Ohio State University. ... the new President and CEO of Texas Biomed," said Dr. ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent ... availability of a new report, Sensors for Robotics: Technologies, Markets ... ... ... IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life Sciences ... development of liquid biopsy tests based on the ... an exclusive license agreement with its first international ... liquid biopsy test for prostate cancer, the Prostate ... . This is the first overseas appointment ...
(Date:2/16/2017)... DUBLIN , Feb. 16, 2017 ... the "Synthetic Biology: Global Markets" report to ... ... synthetic-biology products (synthetic genes, biobrick parts, delivery plasmids, chassis ... DNA synthesis and assembly, genome editing, bioinformatics and specialty ...
(Date:2/16/2017)... Feb. 16, 2017   Biostage, Inc. (Nasdaq: ... biotechnology company developing bioengineered organ implants to treat cancers ... trachea, announced today the closing on February 15, 2017 ... of common stock and warrants to purchase 20,000,000 shares ... million. The offering was priced at $0.40 per share ...
(Date:2/16/2017)... DENVER , Feb. 16, 2017 UCHealth ... hospital to utilize LungDirect for pulmonary nodule patient management. ... a nodule, or a spot on the lung, UCHealth ... spent on manual data entry. Stephanie ... been tracking my nodule patients with an Excel spreadsheet, ...
Breaking Biology Technology: